Login to Your Account

Safer schizophrenia drug? Intra-Cellular jumps on data from first phase III

By Jennifer Boggs
Staff Writer

Wednesday, September 16, 2015

Shares of Intra-Cellular Therapies Inc. hit a 52-week high after unveiling top-line data from the first phase III study of ITI-007, showing the drug met the primary endpoint of antipsychotic efficacy in acutely exacerbated schizophrenia.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription